On October 6, 2021 Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported it will present a poster at the Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held this year from October 7th -10th (Press release, Aadi Bioscience, OCT 6, 2021, View Source [SID1234592087]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present preclinical data evaluating nab-sirolimus (ABI-009) in PTEN-deleted and TSC2-deleted cancer models in comparison with other mTOR inhibitors sirolimus and everolimus and evaluating their effects on important downstream targets S6 and 4EBP1.

Learn more about Aadi’s development of therapies that target the genetic drivers of cancers of the mTOR pathway at www.aadibio.com.

Aadi’s presentation at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC International Conference:

All times noted are U.S. Eastern Time (ET).

Presentation Title: nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts
Author: Shihe Hou, Ph.D., Aadi Bioscience, Inc.
Session: mTOR/PI3-kinase, P138
Session Date/Time: Thursday, October 7, 9:00 a.m. and on-demand throughout conference

The poster will be posted to the Events and Presentations section of Aadi Bioscience’s website after 9 am ET on October 7th.

On October 6, 2021, XOMA (US) LLC ("XOMA"), a wholly-owned subsidiary of XOMA Corporation (the "Company"), reported that entered into a commercial payment purchase agreement (the "Agreement") with Affitech Research AS, a Norwegian biotech company ("Affitech") (Filing, 8-K, Xoma, OCT 6, 2021, View Source [SID1234591012]). Pursuant to the Agreement, XOMA has purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for $6 million. XOMA is eligible to receive an economic interest of 0.50% of net sales of faricimab for a ten-year period following first commercial sales in each applicable jurisdiction. XOMA may pay up to an additional $20 million to Affitech based upon the achievement of certain regulatory and sales milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Agreement contains certain covenants, representations and warranties regarding Affitech’s rights and obligations with respect to the existing licenses and customary covenants and representations for a transaction of this nature.

On October 6, 2021 LianBio, a Princeton, NJ-Shanghai biopharma, reported that it has filed for a $100 million IPO on the NASDAQ exchange (Press release, LianBio, OCT 6, 2021, View Source [SID1234591005]). LianBio currently has a pipeline of nine in-licensed candidates in five therapeutic areas including oncology. The company was formed by US-based Perceptive Investors to bring promising products from its large portfolio of life science companies to China’s market, while LianBio also in-licenses candidates from other companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 6, 2021 Race Oncology ("Race") reported that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene (bisantrene dihydrochloride) (Press release, Race Oncology, OCT 6, 2021, View Source [SID1234591004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is Race’s fifth patent granted for Zantrene in the United States. "This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene", said Race’s CEO & Managing Director, Phillip Lynch.

The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192) and in 2020 (US 10,548,876), further strengthening Race’s IP position for Zantrene.

The patent further expands Race’s IP portfolio in the therapeutic utility of Zantrene (and related chemical structures), in particular – for methods, formulations and compositions that improve the therapeutic efficacy of Zantrene and reduce side effects.

On October 6, 2021 Biogen Inc. (Nasdaq:BIIB) reported it will report third quarter 2021 financial results Wednesday, October 20, 2021, before the financial markets open.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. Following the live webcast, an archived version of the call will be available on the website.